Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.
| Title: | Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine. |
|---|---|
| Authors: | Chiuppesi F; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Salazar MD; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Contreras H; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Nguyen VH; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Martinez J; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Park S; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Nguyen J; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Kha M; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Iniguez A; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Zhou Q; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Kaltcheva T; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Levytskyy R; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Ebelt ND; Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.; Kang TH; Department of Genomic core facility, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.; Wu X; Department of Genomic core facility, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.; Rogers T; University of California San Diego, School of Medicine, Division of Infectious Diseases and Global Public Health, 9500 Gilman Dr, La Jolla, CA 92093; Scripps Research, Department of Immunology and Microbiology, 10550 N Torrey Pines Rd, La Jolla, CA 92037.; Manuel ER; Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.; Shostak Y; Research Business Development, City of Hope, Duarte CA 91010, USA.; Diamond DJ; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.; Wussow F; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA. |
| Source: | BioRxiv : the preprint server for biology [bioRxiv] 2020 Jul 02. Date of Electronic Publication: 2020 Jul 02. |
| Publication Type: | Preprint; Journal Article |
| Language: | English |
| Journal Info: | Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE |
| Abstract: | Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate. |
| Comments: | Update in: Nat Commun. 2020 Nov 30;11(1):6121. doi: 10.1038/s41467-020-19819-1.. (PMID: 33257686) |
| References: | Vaccine. 2013 Sep 6;31(39):4247-51. (PMID: 23523407); J Gen Virol. 2007 Dec;88(Pt 12):3249-3259. (PMID: 18024893); J Virol. 2013 Feb;87(3):1322-32. (PMID: 23152525); J Virol. 2018 Sep 12;92(19):. (PMID: 30045984); PLoS One. 2018 Jan 19;13(1):e0188453. (PMID: 29351298); J Virol. 2004 Apr;78(8):3965-76. (PMID: 15047812); Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):9977-81. (PMID: 1438247); Science. 2020 Aug 21;369(6506):956-963. (PMID: 32540903); J Vis Exp. 2019 Mar 1;(145):. (PMID: 30882796); Lancet. 2020 Jun 13;395(10240):1845-1854. (PMID: 32450106); Nat Commun. 2020 May 20;11(1):2601. (PMID: 32433465); Blood. 2017 Jan 5;129(1):114-125. (PMID: 27760761); Science. 2020 Aug 14;369(6505):806-811. (PMID: 32434945); EBioMedicine. 2020 May;55:102768. (PMID: 32344202); J Virol. 2009 Jul;83(14):7176-84. (PMID: 19420086); N Engl J Med. 2020 May 21;382(21):1969-1973. (PMID: 32227757); Virology. 1997 Nov 24;238(2):198-211. (PMID: 9400593); Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507); Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877); PLoS Pathog. 2014 Nov 20;10(11):e1004524. (PMID: 25412505); J Mol Biol. 1988 Feb 5;199(3):399-413. (PMID: 3351934); J Virol. 1990 Oct;64(10):5029-35. (PMID: 2398534); Methods Mol Biol. 2010;634:421-30. (PMID: 20677001); N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945); Curr Protoc Protein Sci. 2017 Aug 1;89:5.13.1-5.13.18. (PMID: 28762491); Biotechniques. 2006 Feb;40(2):191-7. (PMID: 16526409); Sci Immunol. 2020 Jun 11;5(48):. (PMID: 32527802); J Virol. 1986 Aug;59(2):249-59. (PMID: 3016294); Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127); Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444); J Exp Med. 2005 Jan 3;201(1):95-104. (PMID: 15623576); Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51. (PMID: 1438287); Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462); J Virol. 1987 Jun;61(6):1957-63. (PMID: 3033323); Nat Rev Immunol. 2020 Jun;20(6):339-341. (PMID: 32317716); J Virol. 2011 Oct;85(20):10582-97. (PMID: 21775467); Ann Intern Med. 2020 Mar 3;172(5):306-316. (PMID: 32040960); Vaccine. 1996 Oct;14(15):1451-8. (PMID: 8994321); Cell. 1986 Jun 20;45(6):879-84. (PMID: 3085958); Zentralbl Veterinarmed B. 1966 Feb;13(1):1-13. (PMID: 4288045); Science. 2020 May 29;368(6494):945-946. (PMID: 32385100); Adv Virus Res. 2017;97:187-243. (PMID: 28057259); Virology. 1998 May 10;244(2):365-96. (PMID: 9601507); Cold Spring Harb Symp Quant Biol. 1983;47 Pt 2:723-9. (PMID: 6574869); Vaccine. 1988 Dec;6(6):504-8. (PMID: 2854339); Oncoimmunology. 2017 Aug 11;6(12):e1363138. (PMID: 29209571); J Virol Methods. 2018 Jan;251:30-37. (PMID: 28989096); Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651); Immunity. 2020 Jun 16;52(6):971-977.e3. (PMID: 32413330); Nucleic Acids Res. 1979 Nov 24;7(6):1513-23. (PMID: 388356); Curr Protoc Mol Biol. 2017 Jan 5;117:16.17.1-16.17.18. (PMID: 28060405); Vaccine. 2010 Feb 10;28(6):1547-57. (PMID: 19969118); Viruses. 2020 May 06;12(5):. (PMID: 32384820); Vaccine. 2013 Sep 6;31(39):4241-6. (PMID: 23523410) |
| Grant Information: | U19 AI128913 United States AI NIAID NIH HHS; R01 CA181045 United States CA NCI NIH HHS; P01 CA111412 United States CA NCI NIH HHS; P30 CA033572 United States CA NCI NIH HHS; P50 CA107399 United States CA NCI NIH HHS |
| Entry Date(s): | Date Created: 20200709 Latest Revision: 20240922 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7337387 |
| DOI: | 10.1101/2020.07.01.183236 |
| PMID: | 32637957 |
| Database: | MEDLINE |
Preprint; Journal Article